Phio Pharmaceuticals Corp. Revenue | PHIO

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Phio Pharmaceuticals Corp.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
-	-	-	-	-	4.36 K	21 K	138 K	15 K	19 K	34 K	71 K	399 K	97 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
399 K	4.36 K	88.7 K

Quarterly Revenue Phio Pharmaceuticals Corp.

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21 K	-	57 K	58 K	23 K	-	-	-	-	-	19 K	9 K	10 K	-	34 K	34 K	34 K	-	-	-	29 K	-	92 K	225 K	53 K	-	57 K	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
225 K	9 K	50.3 K

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Jazz Pharmaceuticals plc JAZZ	4.27 B	$ 211.97	-0.84 %	$ 12.9 B	Irlanda
Xenon Pharmaceuticals XENE	7.5 M	$ 35.95	-0.88 %	$ 2.85 B	Canada
Xeris Pharmaceuticals XERS	292 M	$ 10.79	-3.1 %	$ 1.73 B	USA
Kymera Therapeutics KYMR	39.2 M	$ 112.63	-0.73 %	$ 9.52 B	USA
Praxis Precision Medicines PRAX	8.55 M	$ 256.47	-3.03 %	$ 5.77 B	USA
PTC Therapeutics PTCT	1.73 B	$ 62.62	-0.48 %	$ 4.98 B	USA
Arcus Biosciences RCUS	247 M	$ 19.1	-19.58 %	$ 2.05 B	USA
Regeneron Pharmaceuticals REGN	14.3 B	$ 805.67	-0.22 %	$ 84.3 B	USA
X4 Pharmaceuticals XFOR	6.5 M	$ 3.01	-0.33 %	$ 127 M	USA
Rafael Holdings RFL	917 K	$ 1.3	0.78 %	$ 38.2 M	USA
REGENXBIO RGNX	170 M	$ 7.17	-3.11 %	$ 370 M	USA
Royalty Pharma plc RPRX	2.38 B	$ 62.15	-0.16 %	$ 26.7 B	USA
Seer SEER	16.6 M	$ 2.03	2.53 %	$ 112 M	USA
Zymeworks ZYME	26.7 M	$ 28.12	4.48 %	$ 1.45 B	Canada
SIGA Technologies SIGA	94.6 M	$ 3.12	-0.95 %	$ 223 M	USA
Nanobiotix S.A. NBTX	32.6 M	$ 25.83	7.0 %	$ 1.24 T	France
22nd Century Group XXII	17.6 M	$ 0.27	2.13 %	$ 49.7 K	USA
Syndax Pharmaceuticals SNDX	172 M	$ 13.15	-0.75 %	$ 1.14 B	USA
Soligenix SNGX	119 K	$ 0.35	-1.27 %	$ 1.82 M	USA
Intellia Therapeutics NTLA	67.7 M	$ 11.65	-1.6 %	$ 1.26 B	USA
Nuvation Bio NUVB	62.9 M	$ 4.85	1.89 %	$ 1.66 B	USA
Sarepta Therapeutics SRPT	443 M	$ 18.56	-3.18 %	$ 1.86 B	USA
Processa Pharmaceuticals PCSA	5 K	$ 1.76	1.73 %	$ 2.3 M	USA
RedHill Biopharma Ltd. RDHL	8.04 M	$ 0.46	-10.31 %	$ 5.67 B	Israel
SELLAS Life Sciences Group SLS	1 M	$ 12.14	1.34 %	$ 1.32 B	USA
Protara Therapeutics TARA	2.95 M	$ 2.5	-2.34 %	$ 107 M	USA
Relay Therapeutics RLAY	15.4 M	$ 18.41	-0.22 %	$ 3.16 B	USA
Pfizer PFE	62.6 B	$ 29.85	-0.95 %	$ 170 B	USA
Supernus Pharmaceuticals SUPN	719 M	$ 41.21	-0.05 %	$ 2.33 B	USA
Takeda Pharmaceutical Company Limited TAK	4.58 T	$ 19.93	-0.75 %	$ 31.5 B	Japan
Revolution Medicines RVMD	11.6 M	$ 194.28	-1.15 %	$ 36.9 B	USA
Rhythm Pharmaceuticals RYTM	190 M	$ 88.62	-1.75 %	$ 5.76 B	USA
Prelude Therapeutics Incorporated PRLD	12.1 M	$ 3.65	3.4 %	$ 281 M	USA
Zai Lab Limited ZLAB	460 M	$ 24.2	-3.51 %	$ 26.5 B	China
Pulmatrix PULM	7.81 M	$ 1.57	9.79 %	$ 5.73 B	USA
Zentalis Pharmaceuticals ZNTL	67.4 M	$ 2.36	-1.26 %	$ 170 M	USA
Zoetis ZTS	9.47 B	$ 79.62	-0.52 %	$ 35.3 B	USA
Ultragenyx Pharmaceutical RARE	673 M	$ 15.92	-0.62 %	$ 1.57 B	USA
XTL Biopharmaceuticals Ltd. XTLB	451 K	$ 1.87	-3.61 %	$ 1.26 B	Israel
Cleveland BioLabs, Inc. CBLI	263 K	-	-7.31 %	$ 49 M	USA
AC Immune SA ACIU	3.57 M	$ 2.47	-0.8 %	$ 249 M	Schweiz
Five Prime Therapeutics, Inc. FPRX	13.2 M	-	-	$ 1.77 B	USA
Adagene ADAG	7.67 M	$ 2.41	-3.6 %	$ 142 M	China
ADC Therapeutics SA ADCT	81.4 M	$ 1.5	-1.32 %	$ 191 M	Schweiz